Crossmark Global Holdings’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,428
| Closed | -$231K | – | 1439 |
|
|
2020
Q3 | $231K | Buy |
5,428
+180
| +3% | +$7.66K | 0.01% | 1164 |
|
|
2020
Q2 | $252K | Buy |
5,248
+480
| +10% | +$23K | 0.01% | 1111 |
|
|
2020
Q1 | $219K | Buy |
4,768
+20
| +0.4% | +$919 | 0.01% | 1010 |
|
|
2019
Q4 | $285K | Buy |
4,748
+230
| +5% | +$13.8K | 0.01% | 1147 |
|
|
2019
Q3 | $256K | Buy |
4,518
+40
| +0.9% | +$2.27K | 0.01% | 1136 |
|
|
2019
Q2 | $249K | Sell |
4,478
-600
| -12% | -$33.4K | 0.01% | 1182 |
|
|
2019
Q1 | $256K | Buy |
5,078
+60
| +1% | +$3.03K | 0.01% | 1194 |
|
|
2018
Q4 | $202K | Buy |
5,018
+1,430
| +40% | +$57.6K | 0.01% | 1296 |
|
|
2018
Q3 | $249K | Buy |
3,588
+270
| +8% | +$18.7K | 0.01% | 1426 |
|
|
2018
Q2 | $251K | Buy |
+3,318
| New | +$251K | 0.01% | 1423 |
|